-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Response and Resistance: A Tale of Tumor and T Cells

Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies
Program: Scientific Workshops
Session: Engaging Elusive Tumor Cells with Immune Effectors
Friday, December 6, 2024, 2:05 PM-2:41 PM

Frederick Locke, MD

Moffitt Cancer Center, Tampa, FL

Disclosures: Locke: Aptitude Health: Honoraria; American Society of Hematology: Honoraria, Other: travel, accomodation, expenses; BioPharma Communications CARE Education: Honoraria; A2: Consultancy; Allogene: Consultancy, Research Funding; Amgen: Consultancy; Bluebird Bio: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Calibr: Consultancy; Caribou: Consultancy; Kite, a Gilead Company: Consultancy, Other: institutional, travel, accomodation, expenses, Research Funding; Allogene: Other: Institutional, Research Funding; CERo Therapeutics: Research Funding; Moffitt Cancer Center: Patents & Royalties; Communications CARE Education: Honoraria; Clinical Care Options Oncology: Honoraria; Imedex: Honoraria; Society for Immunotherapy of Cancer: Honoraria; Cowen: Consultancy; EcoR1: Consultancy; Gerson Lehrman Group (GLG): Consultancy; Iovance: Consultancy; Janssen: Consultancy; Legend Biotech: Consultancy; Novartis: Consultancy, Research Funding; Sana: Consultancy; Umoja: Consultancy; Pfizer: Consultancy; 2SeventyBio: Other: Institutional, Research Funding; National Cancer Institute: Other: Institutional, Research Funding; Leukemia and Lymphoma Society Scholar in Clinical Research: Other: Institutional, Research Funding.

See more of: Engaging Elusive Tumor Cells with Immune Effectors
See more of: Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies
See more of: Scientific Workshops
<< Previous Presentation | Next Presentation >>